Literature DB >> 10517346

Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.

D Tong1, K Czerwenka, J Sedlak, C Schneeberger, I Schiebel, N Concin, S Leodolter, R Zeillinger.   

Abstract

The invasive potential of tumor cells is usually tested either by in vitro invasion assays which evaluate cell spreading ability in basement membrane-like matrices or by in vivo invasion assays in nude mice. Both methods are laborious and time-consuming. Tumor invasiveness is accompanied by the changes in expression of various genes. The invasive behavior of cells is therefore represented by certain gene expression patterns. The purpose of this study was to investigate whether expression patterns of several genes are characteristic for the invasiveness of cultured cells. We examined the mRNA levels of estrogen receptor (ER), progesterone receptor (PR), estrogen inducible pS2 and plasminogen activator inhibitor-1 (PAI-1) in 23 cell lines derived from benign and malignant breast tissues using a competitive reverse transcription-polymerase chain reaction (cRT-PCR) system. We also evaluated the invasiveness of these cell lines by their ability to penetrate into a collagen-fibroblast matrix. We demonstrate that the gene expression pattern of breast cell lines is clearly associated with their in vitro invasiveness. In general, cells with ER, PR, pS2 but no PAI-1 expression showed a non-invasive phenotype, while cells expressing PAI-1 mRNA but not ER mRNA are invasive. Our study indicates that the invasiveness of breast cancer cell lines is characterized by PAI-1 gene expression and the lack of ER mRNA. This suggests that PAI-1 may participate in the invasive process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517346     DOI: 10.1023/a:1006262501062

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.

Authors:  Sophie Lehn; Nicholas P Tobin; Pontus Berglund; Kristina Nilsson; Andrew H Sims; Karin Jirström; Pirkko Härkönen; Rebecca Lamb; Göran Landberg
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

3.  Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines.

Authors:  Siddarth Chandrasekaran; Yue Geng; Lisa A DeLouise; Michael R King
Journal:  Biomaterials       Date:  2012-09-17       Impact factor: 12.479

4.  MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells.

Authors:  Xiaoxi Zhang; Haijun Yu; Jessica R Lou; Jie Zheng; Hua Zhu; Narcis-Ioan Popescu; Florea Lupu; Stuart E Lind; Wei-Qun Ding
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.

Authors:  Sarah A Andres; Angelena B Edwards; James L Wittliff
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

6.  Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.

Authors:  Rouba Hage-Sleiman; Stéphanie Herveau; Eva-Laure Matera; Jean-Fabien Laurier; Charles Dumontet
Journal:  BMC Cancer       Date:  2010-04-12       Impact factor: 4.430

7.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

8.  Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.

Authors:  Gideon Y Stein; Nir Yosef; Hadar Reichman; Judith Horev; Adi Laser-Azogui; Angelique Berens; James Resau; Eytan Ruppin; Roded Sharan; Ilan Tsarfaty
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

9.  Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers.

Authors:  Casey M Turk; Katerina D Fagan-Solis; Kristin E Williams; Joseph M Gozgit; Sallie Smith-Schneider; Sharon A Marconi; Christopher N Otis; Giovanna M Crisi; Douglas L Anderton; Manfred W Kilimann; Kathleen F Arcaro
Journal:  Cancer Cell Int       Date:  2012-05-10       Impact factor: 5.722

10.  Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel.

Authors:  Aliakbar Taherian; Tahereh Mazoochi
Journal:  Iran J Basic Med Sci       Date:  2012-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.